tirzepatide and diabetes Semaglutide treatment leads to weight loss in type 1 Mounjaro (tirzepatide) for the Treatment

The people who maintain their weight loss long term are those who planned for maintenance from day one

Each treatment plan includes ongoing support and monitoring from our team to ensure progression is healthy, safe, and efficient

Mounjaro is the first and only approved once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist

It works by stimulating the release of insulin, a hormone that helps control blood sugar, and by reducing the production of glucagon, another hormone that raises blood sugar levels

A related FDA decision in the US is expected by April 2026

[DOI] [PubMed] [Google Scholar] 90.Reiner D.J., Mietlicki-Baase E.G., McGrath L.E., Zimmer D.J., Bence K.K., Sousa G.L., Konanur V.R., Krawczyk J., Burk D.H., Kanoski S.E., et al